Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pulrodemstat
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pulrodemstat (CC-90011) is a potent, selective, reversible, and orally active small molecule inhibitor of lysine-specific demethylase 1 (LSD1). By inhibiting LSD1, it increases the expression of tumor-suppressing genes and decreases the expression of tumor-promoting genes, leading to reduced tumor cell growth. Pulrodemstat has demonstrated clinical activity in patients with advanced solid tumors and relapsed/refractory lymphoma, particularly neuroendocrine neoplasms. The drug was originally developed by Quanticel Pharmaceuticals and further developed by Celgene. It has been evaluated in phase I/II trials for various cancers including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), non-Hodgkin lymphoma, acute myeloid leukemia (AML), prostate cancer, and other solid tumors.
- Other names
- pulrodemstat
02
Targets
KDM1A (LSD1)
Beyond the preview
Go deeper on pulrodemstat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pulrodemstat.